

10  
FAX RECEIVED

JAN 08 2001

SN 09/475,385

OFFICIAL

GROUP 1600

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#12/B  
nb  
01/10/02

Applicant: Mathew et al.  
47 5365

Examiner: Ruixiang, Li

Serial No: 09/475,385

Group Art Unit: 1646

Filed: 12/30/99

Docket No: UNT-LLTII

Title: LLT USES IN IMMUNE SYSTEM MODULATION

**AMENDMENT; AND RESPONSE TO OFFICE ACTION MAILED  
DECEMBER 5, 2001**

CERTIFICATE OF FACSIMILE TRANSMISSION TO THE PATENT AND TRADEMARK OFFICE UNDER 37 CFR 1.8(a)(1)(i)(B) IN ACCORDANCE WITH 37 CFR 1.6(d): THE UNDERSIGNED HEREBY CERTIFIES THAT THIS CORRESPONDENCE IS BEING SENT BY FACSIMILE TRANSMISSION TO 1-703-305-3014 ADDRESSED TO THE COMMISSIONER OF PATENTS, ATTENTION TO EXAMINER RUIXIANG, WASHINGTON, D.C., ON JANUARY 7, 2002.

BY: DENISE L. MAYFIELD

*Denise L. Mayfield*

Dear Sir:

The present paper is being filed as a complete response to the Office Action mailed December 5, 2002. The present paper is submitted to be timely filed, as it is being filed by the one-month period to respond to the Action, said period to expire on January 7, 2002 (January 5, 2002 being a Saturday). No extension of time is deemed necessary. However, should such a request for extension of time is deemed appropriate, please consider this paper to constitute a request for the appropriate extension of time. Any required fees should be charged to the applicant's deposit account.

**AMENDMENT**

Please amend the Specification as follows:

At page 6, after 'The nucleotide sequence', line 11, insert -- (SEQ ID NO: 5) --.

At page 6, line 11, after 'predicted translation of LLT1', insert -- (SEQ ID NO: 2) --.

At page 6, line 11, after 'underlined', insert -- (SEQ ID NO: 1) --.